Viridian Therapeutics, Inc. DE (NASDAQ:VRDN)
| Market Cap | 2.41B+8.1% |
| Revenue (ttm) | 71.13M+23220.3% |
| Net Income | -386.97M-12.5% |
| EPS | -3.53+13.1% |
| Shares Out | 113.29M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 943,151 |
| Open | 22.43 |
| Previous Close | 22.29 |
| Day's Range | 21.18 - 22.70 |
| 52-Week Range | 13.18 - 34.29 |
| Beta | 0.96 |
| Analysts | Buy |
| Price Target | 36.14(+70.15%) |
| Earnings Date | Nov 4, 2026 |
About VRDN
Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen Therapeutics, Inc., before changing its name to Viridian Therapeutics, Inc. in January 2021.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$VRDN stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in VRDN holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by VRDN's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
VRDN Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New VRDN patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to VRDN from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in VRDN
| ETF | Est. Holding Size |
|---|---|
| XBIState Street SPDR S&P Biotech ETF | $93.33M |
| VTIVanguard Morningstar Total Stock Market ETF | $63.50M |
| IWMiShares Russell 2000 ETF | $52.09M |
| VXFVanguard Extended Market ETF | $21.42M |
| IWNiShares Russell 2000 Value ETF | $17.21M |
| SCHASchwab U.S. Small-Cap ETF | $10.47M |
Estimated from each fund’s disclosed top holdings × AUM
VRDN Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from VRDN’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score